Bristol Myers Squibb Company and bluebird bio could learn this week whether the European Medicines Agency will recommend pan-EU marketing approval for idecabtagene vicleucel (ide-cel), the cell-based gene therapy they have co-developed to treat multiple myeloma.
Ide-cel, which was approved in the US in March under the brand name Abecma, is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?